newsfilter
← Latest News
PR Newswire·

TC Biopharm Announces Pricing of Upsized $17.5 Million Initial Public Offering and Nasdaq Listing

EDINBURGH, Scotland, Feb. 10, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and